Drug Interactions between eculizumab and iptacopan

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Concomitant use of iptacopan with other complement inhibitor therapies indicated for the treatment of paroxysmal nocturnal hemoglobinuria may increase the risk of additive adverse effects. These include serious, life-threatening, or fatal infections caused by encapsulated bacteria, decreased platelet counts, and increased blood pressure and cholesterol. Iptacopan is an oral proximal complement inhibitor that targets factor B of the alternative pathway of the complement cascade, while other complement inhibitors such as ravulizumab and eculizumab are intravenously administered terminal complement inhibitors that bind to the complement protein C 5 with high affinity. The primary safety and efficacy data for iptacopan was reported in two phase 3, open label trials. In both trials, iptacopan was administered as monotherapy, either in patients who had previously received anti-C5 treatment (APPLY-PNH) or in those who had not previously been treated with complement inhibitors (APPOINT-PNH). However, one multicenter, open-label, single-arm phase 2 trial (n=10) involved iptacopan given orally at 200 mg twice daily as an add-on therapy in patients already receiving eculizumab treatment reported no deaths or treatment-related serious adverse events during the study period.

MANAGEMENT: Concomitant use of iptacopan with complement inhibitors used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH) including eculizumab and ravulizumab, should generally be avoided. According to some authorities the combination of iptacopan with other complement inhibitor therapies for PNH is considered contraindicated, unless medically justified. The manufacturer's product information for these medicines should be consulted for dosage and timing recommendations when switching from one therapy to the other.